Use of convalescent plasma therapy in coronavirus-infected patients does not help in reducing mortality or progression to severe Covid-19
New Delhi: Use of convalescent plasma therapy in coronavirus-infected patients does not help in reducing mortality or progression to severe Covid-19, according to Indian Council of Medical Research (ICMR).
Plasma The convalescent plasma (CP) therapy involves taking antibodies from the blood of a person who has recovered from Covid-19 and transfusing those antibodies into an active coronavirus patient to help kickstart the immune system to fight the infection.
A total of 464 participants were enrolled for the study.
The National Task Force for Covid-19 has reviewed and approved this study, it said.
Covid-19
The CP was not associated with reduction in mortality or progression to severe Covid-19, the study said.
The study trial included 464 moderately ill coronavirus infected hospitalised patients, of whom 235 were given convalescent plasma along with best of standard care while 229 received only standard care, as per the study.
